Michael Chi Sells 2,054 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the sale, the insider now owns 184,947 shares in the company, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Michael Chi also recently made the following trade(s):

• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.00, for a total transaction of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00.

Hims & Hers Health Stock Performance

NYSE:HIMS traded up $1.36 during trading hours on Tuesday, hitting $32.21. The company’s stock had a trading volume of 13,937,724 shares, compared to its average volume of 9,851,665. Hims & Hers Health, Inc. has a 52-week low of $8.09 and a 52-week high of $35.02. The business’s 50-day moving average is $22.01 and its two-hundred day moving average is $19.94. The company has a market capitalization of $7.04 billion, a PE ratio of 73.21 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period in the prior year, the business posted ($0.04) earnings per share. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several large investors have recently bought and sold shares of HIMS. Nisa Investment Advisors LLC raised its stake in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the last quarter. Quest Partners LLC raised its position in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the second quarter worth about $111,000. CWM LLC lifted its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Quarry LP increased its stake in shares of Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after purchasing an additional 2,913 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on HIMS. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Finally, TD Cowen restated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $21.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.